Provided by Tiger Trade Technology Pte. Ltd.

KALA BIO

0.3980
-0.0085-2.09%
Post-market: 0.40000.0020+0.50%19:55 EST
Volume:634.86K
Turnover:259.64K
Market Cap:362.58M
PE:-0.07
High:0.4414
Open:0.4200
Low:0.3801
Close:0.4065
52wk High:20.60
52wk Low:0.3528
Shares:911.00M
Float Shares:911.00M
Volume Ratio:0.91
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8254
EPS(LYR):-10.1450
ROE:-708.34%
ROA:-65.81%
PB:-41.84
PE(LYR):-0.04

Loading ...

Why Did KALA BIO Shares Jump Over 22% After Hours?

Benzinga_recent_news
·
Dec 04, 2025

Kala Bio Inc. Files Initial Beneficial Ownership Statement Naming Oxford Finance LLC

Reuters
·
Dec 04, 2025

Top Midday Gainers

MT Newswires Live
·
Dec 02, 2025

KALA BIO Inc: Continuing to Evaluate and Redevelop Co's Product Candidates While Actively Exploring Strategic Opportunities

THOMSON REUTERS
·
Dec 01, 2025

KALA BIO Inc - David E. Lazar Appointed as Kala's CEO and Chairman

THOMSON REUTERS
·
Dec 01, 2025

KALA BIO Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

GlobeNewswire
·
Dec 01, 2025

Kala Bio Inc. Files Initial Statement of Beneficial Ownership for CEO and Director David E. Lazar

Reuters
·
Nov 27, 2025

What Sparked KALA BIO's Nearly 38% Surge Overnight?

Benzinga
·
Nov 26, 2025

BRIEF-Kala Bio Inc - On Nov 21, Board Terminated Without Cause The Employment Of Mary Reumuth, Company's Chief Financial Officer

Reuters
·
Nov 26, 2025

KALA BIO Raises $1.8M in Preferred Stock Offering

TIPRANKS
·
Nov 26, 2025

KALA BIO Inc - on Nov 21, Board Terminated Without Cause the Employment of Mary Reumuth, Company's Chief Financial Officer

THOMSON REUTERS
·
Nov 26, 2025

KALA BIO Inc - on Nov 21, Board Appointed David Lazar as CEO of Co

THOMSON REUTERS
·
Nov 26, 2025

Kala Bio Inc. Announces $6 Million Private Placement of Preferred Shares

Reuters
·
Nov 26, 2025

Kala Bio Q3 EPS $(1.07) Beats $(1.45) Estimate

Benzinga
·
Nov 19, 2025

Top News Today: Stocks Mixed as AI Selloff Slows

Dow Jones
·
Nov 15, 2025

Kala Bio Delays Quarterly Financial Report Filing

Reuters
·
Nov 15, 2025

KALA BIO Inc - on Nov 10, Received Nasdaq Deficiency Letter for Non-Compliance - SEC Filing

THOMSON REUTERS
·
Nov 13, 2025

Kala Bio Faces Nasdaq Delisting Risk Over Market Value Compliance

Reuters
·
Nov 13, 2025

Kala Bio Secures $375,000 Convertible Loan from Private Investor

Reuters
·
Nov 10, 2025

KALA BIO Inc expected to post a loss of $1.45 a share - Earnings Preview

Reuters
·
Nov 07, 2025